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Abstract
In this paper, currently available systemic treatment options (regorafenib, 
trifluridine/tipiracil, re-challenge chemotherapy, mitomycin C plus capecitabine) 
for pretreated patients with metastatic colorectal cancer are discussed and com-
pared in terms of their efficacy and safety profiles. Treatment of these patients has 
remained a challenge for oncologists. The evidence from clinical trials is encourag-
ing. Knowledge of response biomarkers and/or prognostic factors may be helpful in 
the identification of patients who could benefit most from the treatment. Adequate 
medication compliance can be achieved due to awareness of toxicity risk among 
both physicians and cancer patients and appropriate prevention and management 
of adverse events.
Keywords: metastatic colorectal cancer, regorafenib, trifluridine/tipiracil, 
re-challenge chemotherapy, mitomycin C plus capecitabine
1. Introduction
To this date, management of heavily pretreated patients with metastatic 
colorectal cancer, who present with good performance status and adequate organ 
function reserve, constituted a challenge for oncologists. However, two anticancer 
therapies dedicated for this specific group of patients became available nowadays. 
One of them is regorafenib, an oral inhibitor of protein kinases associated with 
angiogenesis. Another one is trifluridine/tipiracil (TAS-102), an orally administered 
combination of a thymidine-based nucleic acid analog, and tipiracil hydrochlo-
ride, a thymidine phosphorylase inhibitor. Treatment with both anticancer agents 
contributed to a significant improvement of overall survival (OS) and progression-
free survival (PFS) in randomized III phase studies of Caucasian (CORRECT and 
TERRA) and Asian patients (CONCUR and RECOURSE). Recently, clinical benefits 
associated with administration of both drugs and good tolerability thereof were 
also confirmed in an observational study, REGOTAS. The aim of currently ongoing 
trials is to evaluate the efficacy and safety of regorafenib and TAS-102 combined 
with other anticancer drugs in metastatic colorectal cancer patients. While prelimi-
nary results of some of those studies seem promising, more evidence is needed to 
formulate any clinically relevant conclusions.
Another treatment option in metastatic colorectal cancer is re-induction of 
previously used chemotherapy with oxaliplatin- or irinotecan-based regimens. 
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Importantly, the time elapsed since completion of the primary treatment to the 
re-induction should not be shorter than 9 months. Finally, patients with metastatic 
colorectal cancer can receive chemotherapy with mitomycin C plus capecitabine. 
This generally neglected treatment option seems particularly reasonable in the case 
of countries in which regorafenib and trifluridine/tipiracil have been registered but 
are not reimbursed.
The aim of this review paper is to discuss the therapeutic options that could be 
used in metastatic colorectal cancer patients after three or more lines of systemic 
therapy.
2. Regorafenib
Regorafenib (BAY 73-4506) is a low-molecular-weight diphenylurea multikinase 
inhibitor of VEGFR1-3, c-KIT, TIE-2, PDGFR-β, FGFR-1, RET, RAF-1, BRAF, and 
p38 MAP kinase for oral administration. This agent has been registered for patients 
with pretreated metastatic colorectal cancers and refractory gastrointestinal 
stromal tumors (GIST) [1, 2]. Regorafenib is administered at 160 mg daily (q.d.) for 
3 weeks of each 4-week cycle (3 week on, 1 week off), until disease progression or 
drug intolerance, whichever first.
2.1 Trials
In a registration phase III trial, CORRECT (regorafenib monotherapy for previ-
ously treated metastatic colorectal cancer), 760 patients were randomized in a 2:1 
ratio to receive regorafenib or placebo. The majority of patients were Caucasians 
(the study included only 111 Asians). Median OS turned out to be significantly 
longer in the regorafenib group than in the placebo group (6.4 vs. 5.0 months) 
[3]. In another randomized double-blind phase III trial, CONCUR, 204 patients 
with metastatic colorectal cancer after at least two lines of systemic therapy were 
randomized in a 2:1 ratio to receive regorafenib or placebo. All patients were 
Asians. Median OS in the regorafenib arm and placebo arm was 8.8 and 6.3 months, 
respectively. The results of this trial confirmed previous observations about the 
regorafenib efficacy. Toxicity profiles of regorafenib in both studies mentioned 
above were essentially similar [4]. However, these promising findings were not 
confirmed in another trial, PREVIUM, including patients with KRAS- or BRAF-
positive metastatic colorectal cancer treated previously with FOLFOXIRI plus 
bevacizumab; median OS and median PFS in this group were 3.3 and 2.2 months, 
respectively [5].
2.2 Predictive markers
According to Komori et al., colorectal cancer patients who showed early 
decrease in carbohydrate antigen 19-9 (Ca19-9) levels had significantly longer PFS 
after regorafenib than individuals in whom this marker remained elevated (3.7 vs. 
2.0 months). Multivariate analysis confirmed that early decrease in Ca19-9 level 
was a significant independent predictor of better response to regorafenib [6].
The authors of the CORRECT study analyzed an association between mutational 
status of the tumor and survival. The study demonstrated that the presence of 
KRAS-wild type and PIK3CA-wild type in primary tumor was a biomarker of PFS 
benefit [7]. In another study, conducted by Ma et al., the lack of EGFR expression 
turned out to be associated with longer PFS and OS (14 vs. 2.5 months and 19.7 vs. 
9.6 months, respectively). While the presence of KRAS-wild type correlated with 
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longer OS, no significant association was found between this biomarker and PFS 
[8]. Furthermore, multivariate analysis documented prognostic value of tumor’s 
location in the right or left side of the abdominal cavity, with better prognosis 
observed in the case of the left-sided malignancies [8].
RECIST 1.1 is an established instrument to assess a response to anticancer treat-
ment based on radiologically determined cumulative diameter of target lesions. 
Cavitation of lung metastases assessed on CT scans at the baseline and at 8 weeks of 
regorafenib therapy seems to be a novel radiological predictor of PFS [9].
2.3 Toxicity
Adverse event (AE) profile of regorafenib is similar as in the case of other 
tyrosine multikinase inhibitors, and the AEs of this agent are generally manageable. 
The most common non-hematological toxicity, which may worsen patient’s quality 
of life, is hand-foot skin reaction (HFSR) (54%) [10–12]. Hence, many patients 
who experienced this AE may require treatment modification [10]. Interestingly, 
the incidence of HFSR seems to vary by primary tumor type. According to litera-
ture, HFSR symptoms can be found in up to 50% of regorafenib-treated patients 
with hepatocellular carcinoma, 60.2% of individuals with GIST, and 46.6% of 
persons with metastatic colorectal cancer [11]. The second most common AE in 
regorafenib-treated patients is arterial hypertension. Based on the data from five 
clinical trials, the overall incidence of arterial hypertension in regorafenib-treated 
patients can be estimated at 44.4% and the incidence of high-grade (G3 and higher) 
hypertension at 12.5%. Similar to HFSR, the risk of this AE seems to vary according 
to tumor type [13].
Treatment with regorafenib may also contribute to all-grade hepatotoxicity (bili-
rubin, AST, ALT, and ALP elevation), an AE observed in approximately one-third 
of patients treated with this anticancer agent [14].
Other AEs frequently associated with regorafenib treatment are oral mucositis, 
fatigue, nausea, weight loss, and diarrhea [12, 15]. All-grade anorexia was shown 
to occur more often in patients who had been previously treated with tyrosine 
multikinase inhibitors. On the other hand, patients from this group less commonly 
presented with a high-grade AST elevation [12].
The incidence of hematologic toxicities, such as thrombocytopenia, anemia, 
neutropenia, and leukopenia, varies between 22% (thrombocytopenia) and 13% 
(leukopenia). However, high-grade (G3 or higher) hematologic toxicities are 
relatively rarely observed in regorafenib-treated patients [16].
2.4 Regorafenib combined with other anticancer agents
In a phase I study, regorafenib combined with an anti-VEGF inhibitor, cetux-
imab, provided a clinical benefit, defined as the presence of stable disease or partial 
response. However, these promising preliminary findings need to be verified in 
future studies [17].
Combination therapy with regorafenib and FOLFIRI produced highly promis-
ing results, with overall disease control rate (DCR), median PFS, and median OS 
equal to 58.5%, 6.0 and 12.0 months, respectively [8]. An objective response rate 
to regorafenib combined with modified FOLFOX (mFOLFOX6) as the first-line 
treatment was no better than that observed in historical controls, with 85.4% DCR 
and median PFS of 8.5 months [18]. Negative results, specifically the lack of either 
OS or PFS benefit, were obtained in a study investigating the efficacy and toxicity 
of regorafenib plus ruxolitinib, a Janus kinase/signal transducer and activator of 
transcription (JAK-STAT) signaling pathway [19].
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3. Trifluridine/tipiracil hydrochloride
TAS-102 is a new oral anti-metabolite drug, a 1:0.5 mixture of a thymidine-based 
nucleoside analog, alpha,alpha,alpha-trifluorothymidine (trifluridine: FTD), and 
thymidine phosphorylase inhibitor (tipiracil hydrochloride: TPI) [20–23]. FTD 
inhibits thymidylate synthase (TS), the key enzyme involved in DNA synthesis, 
whereas trifluridine incorporates into DNA via phosphorylation and initiates DNA 
fragmentation [20–22]. TPI enhances the exposure to FTD, improves its bioavail-
ability, and increases the durability of response to this agent [24, 25]. Pre-exposure 
to 5-FU was shown to enhance FTD incorporation into DNA and to increase 
antitumor activity of this agent, as shown by lesser viability and proliferation of 
cancer cells [26]. TAS-102 proved to be effective in GI malignancies with inherent 
or acquired resistance to 5-FU, as well as in 5-FU-sensitive tumors [20, 21]. TAS-102 
has recently been approved as the third-line treatment for adults with refractory 
metastatic colorectal cancer, patients with contraindications to currently available 
standard chemotherapy and biological therapy in the EU and USA, and individuals 
with unresectable advanced or recurrent colorectal cancer in Japan. The standard 
regimen is 35 mg/m2 twice a day on days 1–5 and 8–12 of each 28-day cycle [24, 27].
3.1 Trials
The efficacy and safety of TAS-102 were a subject of a double-blind randomized 
phase II trial including Japanese patients with metastatic colorectal cancer. The 
patients were randomized in a 2:1 ratio to either TAS-102 or placebo arm. Median 
OS in the TAS-102 arm turned out to be longer than in the placebo arm (9.0 vs. 
6.6 months). The most common AEs were hematologic toxicities, with grade 3 or 4 
of neutropenia found in 50% of TAS-102-treated patients [28].
In a randomized double-blind phase III registration trial, TERRA, Asian patients 
with metastatic colorectal cancer who previously received at least two lines of sys-
temic treatment were randomized in a 2:1 ratio to either TAS-102 or placebo group. 
The study confirmed the efficacy of TAS-102 in Asian population. Median OS in the 
TAS-102 arm was significantly longer than in the placebo group (7.8 vs. 7.1 months). 
Moreover, the TAS-102-treated patients had significantly lower mortality risk and 
significantly longer median survival follow-up time [29].
In a double-blind phase III registration trial, RECOURSE, 800 patients from 
Europe, North America, and Asia were randomly assigned to receive TAS-102 or 
placebo. PFS for the TAS-102 and placebo arm was 2.0 and 1.7 months, respectively. 
Patients from the TAS-102 arm had significantly longer median OS and significantly 
longer median time to worsening performance status (7.1 and 5.7 months, respec-
tively) than individuals from the placebo arm (5.3 and 4.0 months, respectively). 
One-year OS rates for the TAS-102 and placebo arm were 27 and 18%, respectively 
[30]. Those promising results were further confirmed on a subgroup analysis; 
median OS for TAS-102-treated patients from the USA, Japan, EU, and Spain ranged 
between 6.5 and 7.8 months as compared with 4.3–6.7 months for the respective 
placebo arms, whereas median PFS in the TAS-102 and placebo groups amounted to 
2.0–2.8 and 1.7–1.8 months, respectively [31, 32].
3.2 Predictors
Genetic polymorphisms in homologous recombination pathway seem to be a 
predictor of therapeutic response in metastatic colorectal cancer patients treated 
with TAS-102. According to Suenaga et al., TAS-102-treated patients with a combi-
nation of ENT1 rs760370, MATE1 rs2289669, and OCT2 rs316019 single-nucleotide 
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polymorphisms of genes involved in trifluridine metabolism and thymidine 
phosphorylase inhibitor excretion had significantly longer PFS and OS [33]. Also, 
single-nucleotide polymorphisms of genes involved in homologous recombination, 
such as ATM and XRCC3, could be predictive and prognostic markers in metastatic 
colorectal cancer treated with TAS-102. The TAS-102-treated patients who car-
ried any G allele in ATM rs609429 polymorphism had significantly longer OS and 
nonsignificantly longer PFS than carriers of the C/C variant. Also, the presence of 
any A allele in XRCC3 rs861539 polymorphism was shown to be associated with 
significantly longer OS and PFS in TAS-102-treated patients [34].
Patients with ≥ grade 2 chemotherapy-induced neutropenia (absolute neutrophil 
count <1500/mm3) at 1 month (CIN-1-month) of TAS-102 therapy had longer 
median PFS (3.0 vs. 2.4 months) and OS (14.0 vs. 5.6 months) than those without 
the neutropenia. The presence of neutropenia at 1 month of TAS-102 treatment and 
higher baseline CEA levels were identified as independent predictors of OS [35]. In 
another study, grade 3 or 4 CIN-1-month was shown to be associated with longer 
PFS than grade 0-2 CIN-1-month (4.3 vs. 2.0 months). Moreover, G3 or G4 neu-
tropenia during the first cycle of TAS-102 therapy turned out to be associated with 
significantly higher DCR (72.2%) than grade 0–2 neutropenia (72.2 vs. 30.9%) [36]. 
Finally, a significant association was found between baseline creatinine clearance 
rate of less than 57.1 mL/min prior to TAS-102 administration and the incidence of 
G3 or G4 neutropenia after introduction of this agent [37].
Also, longer time elapsed since the onset of the first-line therapy to disease 
progression (more than 18 months) seems to be a predictor of better response to 
TAS-102 therapy. In one study, median PFS in TAS-102-treated patients with the 
time to progression exceeding 18 months was longer than in those who received the 
first-line therapy ≤18 months before (7 vs. 5 months) [38]. These findings were later 
confirmed in a meta-analysis conducted by Chen et al. [39].
Kwakman et al. identified KRAS-wild type tumor, good performance status 
(PS0 or PS1), and normal serum levels of lactate dehydrogenase and alkaline 
phosphatase as independent predictors of better response to TAS-102 treatment. 
All these factors correlated positively with longer OS. Patients with KRAS-wild 
type tumors had longer median OS than those with KRAS-mutated malignancies 
(6.9 vs. 4.9 months), and median OS in persons with ECOG PS0–1 turned out to be 
longer than in individuals with worse performance status (5.9 vs. 3.2 months) [40]. 
However, in a meta-analysis involving the data of 1318 patients who received TAS-
102, OS was significantly longer than in the study mentioned above, regardless the 
KRAS mutation status. Furthermore, the treatment response was not influenced by 
the number of metastatic sites (1, 2, or more) [39]. Also, in a subgroup analysis of 
patients participating in the RECOURSE trial, neither OS nor PFS correlated with 
the KRAS status, as well as with patients’ age and ethnicity [31].
ECOG performance status (PS0 or PS1), the number of metastatic sites (1 or 2), 
and the time elapsed since the diagnosis of the first metastasis (18 months or longer) 
were identified as prognostic factors in the RECOURSE trial; however, none of those 
factors turned out to be a predictor of therapeutic response [30].
3.3 Toxicity
Hematologic toxicities, including leukopenia, neutropenia, and anemia, and 
gastrointestinal toxicities, such as nausea/vomiting, diarrhea, and the loss of appe-
tite, as well as fatigue of various grade, were the most frequent side effects observed 
in patients treated with trifluridine/tipiracil [40–45]. The most common grade 3/4 
toxicity was myelosuppression (neutropenia, anemia, febrile neutropenia) [46]. 
In turn, cardiac ischemia seems to be one of the rarest AEs observed during the 
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therapy with TAS-102, which implies that this agent might constitute a reasonable 
option for patients with cardiovascular contraindications for 5-FU treatment [47].
Based on available evidence, TAS-102 seems to be a convenient, manageable, and 
safe agent to be used in daily clinical practice.
According to the data from the RECOURSE and J003 trials, severe AEs (SAEs) 
occurred in 27.7% of patients treated with TAS-102. In more than 50% of the 
patients, the toxicity necessitated a delay or interruption of TAS-102 therapy or 
dose reduction [41]. However, the incidence of SAEs and AEs leading to treatment 
discontinuation in TAS-102 and placebo arms was essentially similar, and fatal 
AEs turned out to be more common in the placebo group [41]. Furthermore, in an 
open-label expanded-access program, TAS-102 had similar safety profiles in older 
(≥65 years) and younger (<65 years) patients [48].
Finally, the occurrence of AEs had no significant impact on the quality of life 
and performance status of patients participating in the RECOURSE trial, even in 
those in whom TAS-102 had to be discontinued because of its toxicity [49].
3.4 TAS-102 combined with other anticancer drugs
In preclinical studies, TAS-102 combined with cytotoxic drugs (oxaliplatin, 
irinotecan) showed enhanced activity against recurrent and chemo-naïve colorec-
tal cancers [50, 51]. Also, the regimes including TAS-102 and targeted therapies 
(cetuximab, panitumumab) or antiangiogenic agents (nintedanib, bevacizumab) 
were shown to be effective against colorectal cancer in preclinical studies [52, 53].
One phase I/II study demonstrated a promising efficacy and moderate toxicity 
of TAS-102 plus bevacizumab in patients with metastatic and refractory colorectal 
cancer [54].
The aim of currently ongoing TRiflUridine/tipiracil in Second-line sTudY phase 
II/III study, the results of which will be available in 2022, is to determine DCR, 
response rate (RR), OS, PFS, safety profile, and time to treatment failure of trifluri-
dine/tipiracil plus bevacizumab and irinotecan, fluoropyrimidine plus bevacizumab 
as the second-line treatments in patients with metastatic colorectal cancer who 
failed to respond to the first-line oxaliplatin-based therapy [55].
4. Regorafenib vs. TAS-102
An indirect comparison of regorafenib and TAS-102 based on published evi-
dence from PubMed, Cochrane, and other databases suggests that these two agents 
did not differ in terms of PFS and OS benefit. However, regorafenib seems to 
produce all-grade toxicity more often than TAS-102 [56]. The most common forms 
of grade ≥3 toxicity found in regorafenib-treated patients were hepatotoxicity and 
palmar-plantar erythema, whereas individuals who received TAS-102 most often 
suffered from neutropenia [57, 58]. The similar efficacy of regorafenib and TAS-
102 was confirmed in REGOTAS study (regorafenib vs. TAS-102 as salvage-line in 
patients with colorectal cancer refractory to standard chemotherapies: a multicenter 
observational study, UMIN 000020416) which showed no significant differences in 
OS and PFS of patients treated with one of those agents [59].
A subgroup analysis conducted within the framework of a retrospective study 
of Asian patients demonstrated that regorafenib was significantly more efficacious 
in individuals younger than 65 years, whereas TAS-102 provided greater OS benefit 
in persons aged 65 years or older [60]. Those findings are consistent with the results 
of the REGOTAS trial in which regorafenib-treated patients ≥65 years of age, with 
modified Glasgow Prognostic Score equal to 2 (GPS 2), had shorter OS and PFS 
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than individuals who received TAS-102 [59]. The same study identified modified 
GPS before later-line chemotherapy as the strongest predictor of OS in patients with 
metastatic colorectal cancer [59].
Nothing has been known about the efficacy and toxicity of TAS-102 in patients 
treated previously with regorafenib since publication of Kotani et al.’s study. In 
the latter study, median PFS in patients treated with regorafenib prior to TAS-102 
implementation was 2.0 months as compared with 2.1 months in individuals with 
no history of regorafenib treatment, and median OS in these two groups was 4.7 
and 6.2 months, respectively [61]. The toxicity of TAS-102, assessed based on the 
incidence of at least grade 3 side effects, was similar regardless of the study group 
[61]. The treatment sequence analysis demonstrated that TAS-102-treated patients 
had longer PFS and OS after a fluoropyrimidine-based therapy-free interval, 3.1 
and 17.7 months, respectively, as compared with 2.2 and 8.1 months, respectively, 
in persons in whom TAS-102 was implemented immediately after the fluoropyrimi-
dine-based therapy. However, no similar association was found between the effi-
cacy of regorafenib and the time elapsed since fluoropyrimidine-based treatment 
discontinuation [62].
The prognosis seems to be also influenced by the sequence of regorafenib and 
TAS-102 administration. Median OS in patients who received crossover treat-
ment with regorafenib followed by TAS-102 was 11.5 months, as compared with 
7.6 months in individuals in whom first TAS-102 and then regorafenib were imple-
mented [57].
5. Re-challenge chemotherapy
Another therapeutic option in heavily pretreated patients with metastatic 
colorectal cancer is re-challenge chemotherapy/re-initiation chemotherapy. 
Re-challenge chemotherapy is defined as the re-introduction of previously used 
chemotherapy with oxaliplatin or irinotecan-based regimens at least 9 months 
after the end of the initial exposure. Re-challenge chemotherapy constitutes an 
important option in patients who still present with good performance status and 
organ function reserve, especially in those in whom the initial chemotherapy was 
discontinued before progression of the disease (e.g., due to cumulative toxicities) 
[63–65]. Such approach did not shorten the period of the best supportive care and, 
more importantly, might prolong OS [65]. According to Chambers et al., clinical 
benefit rate (defined as the proportion of patients with partial response or stable 
disease) after re-challenge chemotherapy was 75.5% and time to progression 
equaled 6.5 months [63]. Moreover, re-challenge chemotherapy after regorafenib 
treatment seems to be a good strategy in heavily pretreated patients with metastatic 
colorectal cancer. According to literature, PFS after re-challenge chemotherapy 
varied between 0.5 and 3.5 months, and 6-month OS reached up to 27.3%. In some 
researchers’ opinion, regorafenib could resensitize cancer patients to previously 
given chemotherapy, but this hypothesis still needs to be verified empirically [66].
Some authors reported the use of re-initiation chemotherapy or second re-
challenge chemotherapy after the development of resistance, but none of these 
approaches is a standard of oncological treatment [63, 64].
6. Combination of capecitabine and mitomycin C (MMC)
MMC is a cytotoxic antibiotic which shows moderate efficacy when used 
as monotherapy in colorectal cancer patients. Upregulation of intra-tumoral 
Multidisciplinary Approach for Colorectal Cancer
8
thymidine phosphorylase, an enzyme converting capecitabine to 5-FU, is the 
primary mechanism through which MMC acts synergistically to capecitabine [67]. 
According to literature, overall response rate in patients with metastatic colorectal 
cancer who received MMC (6 mg/m2 intravenously on day 1 every 3 weeks) plus 
capecitabine (1000 mg/m2 twice daily on days 1–14, followed by a 7-day treatment-
free interval) ranged between 15.2 and 55.5% [68–72]. The majority of patients 
received previously two, three, or even four lines of anticancer therapy. Median 
PFS varied between 1.7 and 5.4 months [68–71, 74] and median OS between 5.4 and 
13 months [68–72, 74]. While those results might be considered disappointing, it 
should be emphasized that all patients were pretreated with many lines of systemic 
therapy and had metastases in multiple locations.
With no doubt, the combination therapy with capecitabine and MMC is dedi-
cated primarily for patients with cumulative side effects after previous treatment 
and/or contraindications to targeted therapies [70]. Furthermore, capecitabine 
plus MMC constitutes a good option of the best supportive care in patients 
who still maintain good performance status and organ efficiency, especially in 
countries in which regorafenib and TAS-102 have been registered but are not 
reimbursed.
Toxicity of capecitabine plus MMC combination is mild, acceptable, and easily 
manageable, and no significant hematological AEs have been reported thus far 
[71, 73–74]. The main non-hematological AEs documented in patients treated 
with this regimen are palmar-plantar erythema, nausea, diarrhea, and fatigue [71, 
73–74].
7. Conclusions
Regorafenib and trifluridine/tipiracil have been authorized for the treatment of 
metastatic colorectal cancer, as the third or further therapy line. The patients are 
eligible for one of those treatments if they present with good performance status 
and adequate bone marrow, liver, and kidney function; hence, aside from clinical 
and molecular biomarker status, also those factors should be considered during 
patient qualification. While the toxicity of both anticancer agents is manageable, 
appropriate control of side effects requires clinical vigilance and good medication 
compliance. In some clinical situations, re-induction/re-challenge of previously 
given chemotherapy with oxaliplatin or irinotecan-based regimens and/or switch-
ing to mitomycin C plus capecitabine might be a reasonable option.
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